307 related articles for article (PubMed ID: 22751600)
1. Adalimumab in psoriatic arthritis.
Salvarani C; Pipitone N; Catanoso M; Chiarolanza I; Boiardi L; Caruso A; Pazzola G; Macchioni P; Di Lernia V; Albertini G
J Rheumatol Suppl; 2012 Jul; 89():77-81. PubMed ID: 22751600
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis.
Saraceno R; Bavetta M; Zangrilli A; Chiricozzi A; Potenza C; Chimenti S; Chimenti MS
Expert Opin Biol Ther; 2013 Sep; 13(9):1325-34. PubMed ID: 23930916
[TBL] [Abstract][Full Text] [Related]
6. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
7. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).
Kavanaugh A; Mease P
J Rheumatol Suppl; 2012 Jul; 89():90-3. PubMed ID: 22751603
[TBL] [Abstract][Full Text] [Related]
8. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
Gladman DD; ; Sampalis JS; Illouz O; Guérette B
J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284
[TBL] [Abstract][Full Text] [Related]
9. Infliximab in psoriatic arthritis.
Cantini F; Niccoli L; Nannini C; Kaloudi O; Cassarà E
J Rheumatol Suppl; 2012 Jul; 89():71-3. PubMed ID: 22751598
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab for psoriasis and psoriatic arthritis.
Goldminz AM; Gottlieb AB
J Rheumatol Suppl; 2012 Jul; 89():86-9. PubMed ID: 22751602
[TBL] [Abstract][Full Text] [Related]
11. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
[TBL] [Abstract][Full Text] [Related]
13. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P
Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
[TBL] [Abstract][Full Text] [Related]
14. Etanercept in psoriatic arthritis.
Spadaro A; Lubrano E; Ferrara N; Scarpa R
J Rheumatol Suppl; 2012 Jul; 89():74-6. PubMed ID: 22751599
[TBL] [Abstract][Full Text] [Related]
15. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up.
Vogelzang EH; Kneepkens EL; Nurmohamed MT; van Kuijk AW; Rispens T; Wolbink G; Krieckaert CL
Ann Rheum Dis; 2014 Dec; 73(12):2178-82. PubMed ID: 25115447
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNFα-therapy as an evidence-based treatment option for different clinical manifestations of psoriatic arthritis.
Köhm M; Burkhardt H; Behrens F
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S109-14. PubMed ID: 26472504
[TBL] [Abstract][Full Text] [Related]
17. Treatment of psoriatic arthritis with biological agents.
Ceponis A; Kavanaugh A
Semin Cutan Med Surg; 2010 Mar; 29(1):56-62. PubMed ID: 20430309
[TBL] [Abstract][Full Text] [Related]
18. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.
Weitz JE; Ritchlin CT
Expert Opin Biol Ther; 2014 Apr; 14(4):515-26. PubMed ID: 24555741
[TBL] [Abstract][Full Text] [Related]
20. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
Chastek B; Fox KM; Watson C; Gandra SR
Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
